Cellectar COO granted 118,000 stock options
Cellectar Biosciences Chief Operating Officer Jarrod Longcor received a grant of stock options as equity compensation.
Rhea-AI Filing Summary
Cellectar Biosciences Chief Operating Officer Jarrod Longcor received a grant of stock options as equity compensation. The award covers 118,000 shares of common stock at an exercise price of $3.14 per share and expires on May 28, 2036.
The option was contingently granted on May 28, 2026 and became effective after stockholders approved the amended 2021 Stock Incentive Plan on July 7, 2026. It vests over three years, with one-third vesting on the first anniversary of May 28, 2026 and the remaining two-thirds vesting in 24 equal monthly installments thereafter.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 118,000 shares
Grant/Award
1 txn
Insider
Longcor Jarrod
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 118,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock option (right to buy) — 118,000 contracts (Direct)
Footnotes (2)
- F1. This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026.
- F2. This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026
Key Figures
Option grant size: 118,000 options
Exercise price: $3.14 per share
Expiration date: May 28, 2036
+3 more
6 metrics
Option grant size
118,000 options
Stock option grant to COO covering common stock
Exercise price
$3.14 per share
Strike price for the COO’s stock options
Expiration date
May 28, 2036
Option term for the COO grant
Vesting period
3 years
From May 28, 2026 with staged vesting
Initial cliff vesting
1/3 of options
Vests on first anniversary of May 28, 2026
Monthly vesting installments
24 installments
Remaining two-thirds vest over 24 months after first anniversary
Key Terms
Stock option, exercise price, vesting, amended 2021 Stock Incentive Plan, +1 more
5 terms
Stock option financial
"This option was contingently granted on May 28, 2026, subject to approval"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "3.1400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This option shall vest over a period of three years from May 28, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
amended 2021 Stock Incentive Plan financial
"subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan"
grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cellectar Biosciences (CLRB) disclose about Jarrod Longcor in this Form 4?
Cellectar Biosciences reported that Chief Operating Officer Jarrod Longcor received a grant of stock options covering 118,000 shares of common stock. These options were issued as equity compensation and reflect a non-cash award linked to the company’s amended 2021 Stock Incentive Plan.
How many Cellectar (CLRB) stock options were granted to the COO and at what price?
The COO received 118,000 stock options, each with an exercise price of $3.14 per share. This price is the amount he must pay to purchase each share if he chooses to exercise the options in the future.
When do Jarrod Longcor’s Cellectar (CLRB) stock options vest?
The options vest over three years starting from May 28, 2026. One-third vests on the first anniversary of that date, and the remaining two-thirds vest in 24 equal monthly installments over the following two years.
What approvals were required for the Cellectar (CLRB) COO option grant?
The option grant was contingent on stockholder approval of Cellectar’s amended 2021 Stock Incentive Plan. Stockholders approved the plan at the 2026 Annual Meeting of Stockholders held on July 7, 2026, making the contingent grant effective.
What is the expiration date of the Cellectar (CLRB) stock options granted to the COO?
The stock options granted to the COO expire on May 28, 2036. After this date, any unexercised options will lapse, meaning they can no longer be used to purchase Cellectar Biosciences common stock at the $3.14 exercise price.
Is the Cellectar (CLRB) COO option grant an open-market purchase or a compensation award?
The Form 4 describes the transaction as a grant or award acquisition, not an open-market purchase. This means the options were issued as part of his compensation package rather than bought on the open market for cash.
AI-generated analysis. How Rhea-AI works. Not financial advice.
